Product category:
Evaporation equipment
News Release from: Biotage | Subject: V-10
Edited by the Laboratorytalk Editorial
Team on 18 January 2006
Biotage buys rights to novel evaporation
system
Biotage has acquired the exclusive distribution, production and further development rights to Vapourtec's solvent evaporation system, known as the V-10
After several years in development the V-10 was launched July 2005 The agreement also provides for Vapourtec to deliver further developments and line extensions for the product within 2006
This article was originally published on Laboratorytalk on 11 Jun 2008 at 8.00am (UK)
Related stories
Application of modern tools in organic synthesis
Biotage will sponsor summer programmes at the University of Richmond, VA, US from 21-23 July, 2008 and at the University of Edinburgh, UK, from 29-31 July, 2008
Flash purification system gives faster separations
This Isolera compact Flash purification system enables chemists to achieve better separations in significantly shorter purification run-times, while new features result in maximum purity and yield
The purchase price for the deal consists of an up-front payment and partial payments related to sales development.
The total purchase could reach at maximum £2.3million.
Commercial activities will begin immediately and sales for 2007 are expected to reach between US$5-10million.
Further reading
Fast and reliable microwave scale-up
Biotage will introduce its new Advancer Kilobatch large-scale automated sequential batch microwave synthesiser at the ACS spring 2008 meeting in New Orleans
Evolute CX promises improved sample preparation
Evolute CX is a mixed-mode resin-based SPE sorbent for the extraction of basic drugs from biological fluids using a generic procedure, minimizing method development time for bioanalysts
"Evaporation presents a major bottleneck in chemistry and drug development.
"Vapourtec's V-10 substantially reduces sample drying time for pharmaceutical chemists and fills this void in our product lines," said Jeff Bork, Biotage CEO.
Duncan Guthrie, Vapourtec founder and CEO, adds: "Biotage was the logical choice for partnering.
"It has large scale production facilities, a global sales and service presence and we intend to have an excellent relationship going forward on mutual development programmes".
"Evaporation is a technique employed immediately following synthesis and purification - so it is essential that Biotage offer this technology.
"Vapourtec's V-10 was brought to our attention by some of our largest customers who participated in the product development phase.
"In addition to operating in batch mode at rates up to 40X faster than conventional evaporators, the Vapourtec product also operates in a continuous flow mode, which offers advantages not possible with alternative designs," stated Dave Patteson, president of Biotage's discovery chemistry group.
Biotage is active in life science research with strong technologies, a broad range of operations and a long-term view of the market.
The company offers knowledge and experience in the areas of genetic analysis and medicinal chemistry.
Customers include the worlds top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes.
The company is headquartered in Uppsala and has offices in the USA, Japan, UK and several other European countries.
Vapourtec is a research and technology company located close to Cambridge, UK.
Its strength is strong R and D focusing on the drug discovery and associated industries, with particular emphasis on medicinal chemistry.
Vapourtec works in close partnership with major pharmaceutical companies, with the objective of converting innovative processes into reliable instrumentation.
This Agreement with Biotage gives Vapourtec the opportunity to concentrate on additional novel technologies of benefit to the pharmaceutical industry.
• Biotage: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
